Induced pluripotent stem cells (iPSCs) derived from immunocompatible, patient-specific donor cells have garnered attention for their therapeutic potential in cell replacement strategies. Previous studies show that somatic fibroblasts reprogrammed into induced pluripotent stem cells are indistinguishable in their epigenetic state and developmental potential from blastocyst-derived embryonic stem cells (ESCs). However, the capacity of iPSCs to differentiate into therapeutically relevant and functional cell types in comparison to ESC-derived cell types is largely uninvestigated. Here we have generated human iPSCs by transducing IMR-90 human lung fibroblasts with lentiviral vectors encoding all 6 previously used pluripotency factors, Oct-3/4, Nanog, Sox2, Klf4, Lin28, and c-Myc, under the EF1α promoter, along with an additional EF1α-eGFP lentiviral vector to monitor transgene expression during differentiation. In these studies we induced iPSCs to differentiate in vitro into neural progenitors and their neuronal derivatives. Resulting progenitor cells were characterized by immunochemistry, flow cytometry and then assayed for their differentiation potential to their respective cell lineages. We found that the morphology, time frame for differentiation and marker expression of iPSC-derived progenitors is similar to hESC-derived progenitors for neural differentiation in vitro. We also observed no reemergence of silenced lentiviral transgene expression in iPSC-derived differentiated cell types (i.e. GFP fluorescence). In addition, we developed robust, proliferative iPSC neural progenitors capable of being maintained as adherent monolayer cultures for multiple passages. Our results show that iPSCs have the potential to generate progenitor cell types for future regenerative medicine therapies.
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